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Abstract
Aim—Induction of hepatic stellate cell (HSC) apoptosis is a viable therapeutic strategy to reduce
liver fibrogenesis. Although BH3-only proteins of the Bcl-2 family trigger pro-apoptotic
pathways, the BH3-only proteins mediating HSC apoptosis have not been well defined. Our aim,
using proteasome inhibition as a model to induce HSC apoptosis, was to examine the BH3-only
proteins contributing to cell death of this key liver cell subtype.
Methods—Apoptosis was induced by treating LX-2 cells, an immortalized human hepatic
stellate cell line, and primary rat stellate cells with the proteasome inhibitor MG-132.
Results—Treatment with proteasome inhibitors increased expression of Noxa both at the mRNA
(16-fold) and protein (22-fold) levels indicating that both transcriptional and post-translational
mechanisms contributed to the increase in cellular Noxa levels. Knockdown of Noxa by siRNA
significantly attenuated cell death, mechanistically implicating Noxa as a key apoptotic mediator
of proteasome inhibitor-induced cell death. Given the pivotal role for the anti-apoptotic Bcl-2
protein A1 in activated HSC survival, we determined if Noxa bound to this survival protein. Noxa
was shown to physically bind the anti-apoptotic Bcl-2 protein A1 by co-immunoprecipitation.
Conclusions—Noxa contributes to proteasome inhibitor-induced apoptosis of stellate cells
likely by binding A1. Strategies to therapeutically increase Noxa expression may be useful for
inducing HSC apoptosis.
Keywords
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INTRODUCTION
Hepatic stellate cells (HSCs) are the principle source of hepatic collagen, and therefore, play
a critical role in the development and maintenance of hepatic fibrosis, a nefarious
consequence of all chronic liver diseases regardless of etiopathogenesis1, 2. In health, HSCs
store retinoids and generate little if any collagen3. In response to hepatic injury, these cells
transform into a myofibroblast phenotype and secrete collagen. HSCs appear to undergo a
commitment step to become activated and undergo limited reversion to the quiescent
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phenotype in vivo. Analogous to activation-induced cell death of T-lymphocytes4, activated
HSCs are eliminated by apoptosis5–7. Thus, reversal and/or inhibition of hepatic fibrosis
requires HSC apoptosis. In support of this concept, compounds which inhibit NF-țB
activation (a transcription factor which promotes HSC survival), such as gliotoxin or
sulfasalazine, and the proteasome inhibitor bortezomib reduce hepatic fibrosis by inducing
HSC apoptosis8–11. Information regarding the cellular and molecular mechanisms
regulating HSC apoptosis is limited, however, impeding the development of anti-fibrotic
strategies based on inducing therapeutic HSC apoptosis.
The intrinsic pathway of apoptosis converges on mitochondria resulting in mitochondrial
outer membrane permeabilization with efflux of cytochrome c and other proapoptotic
proteins into the cytosol12. Once in the cytosol, these proteins promote caspase activation
which in turn causes cellular demise13. The mitochondrial pathway of apoptosis is regulated
by members of the Bcl-2 family of proteins14. Members of this family with up to four Bcl-2
homology (BH) domains, such as Bcl-2, Bcl-XL, Mcl-1 and A1, function as guardians of the
mitochondria preventing apoptosis15. The multidomain executioners of mitochondrial
dysfunction are Bax and Bak16, 17 which directly induce mitochondrial dysfunction by
permeabilizing the outer mitochondrial membrane18. The Bcl-2 proteins displaying
sequence homology exclusively in the short BH3 domain are referred to as BH3-only
proteins. These proteins are biosensors of cellular stress and induce apoptosis by functioning
as intracellular death ligands, including Bad, Bid, Bik, Bim, Bmf, Hrk, Noxa and Puma19.
The mechanisms by which they induce cell death remain unresolved, but include direct
ligation and activation of Bax and/or Bak, inhibition of anti-apoptotic multi-domain Bcl-2
proteins, or both14. By whatever mechanism they induce cell death, BH3-only proteins are
critical upstream mediators of the cell death program. The constellation of BH3-only
proteins regulating cell death vary between cell types and remain incompletely understood
in HSCs.
We have employed proteasome inhibitors as a model to help elucidate which Bcl-2 proteins
regulate HSC apoptosis. Proteasome inhibitors rapidly induce apoptosis by complex
mechanisms20. First, these agents prevent NF-țB activation, a transcription factor necessary
for maximal expression of the anti-apoptotic multidomain Bcl-2 protein A121. Indeed, A1 is
an important survival protein for activated HSCs as inhibition of its expression by targeted
siRNA is sufficient to induce cell death of this cell type10. However, the BH3-only proteins
participating in this process remain unclear. Although protease inhibitors enhance Bim
expression, inhibition of Bim by siRNA technology does not reduce HSC apoptosis by
proteasome inhibition10. Another BH3-only protein induced by proteasome inhibitors is
Noxa22–26. Noxa is an attractive BH3-only protein inducing HSC apoptosis given its
potential ability to bind A1 in vitro27. However, information is lacking regarding a potential
role for Noxa in mediating apoptosis of HSC cells.
MATERIAL AND METHODS
Cell lines and culture
The human stellate cell line, LX-2 cells were obtained from Dr. Scott Friedman, Mt. Sinai,
NY28. LX-2 cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM, GIBCO,
Invitrogen, Grand Island, NY) containing high glucose (25 mM), 100,000 units/L penicillin,
100 mg/L streptomycin and 10% fetal bovine serum. Primary rat HSCs were isolated and
cultured as previously described10.
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Quantification of apoptosis
Apoptosis was quantified morphologically by assessing the characteristic nuclear changes
using the DNA binding dye 4ƍ,6-diamidino-2-phenylindole (DAPI, Molecular Probes Inc.,
Eugene, OR) as previously described by us29. Apoptosis was also verified biochemically by
measuring caspase 3/7 activity. Briefly, cells were plated in a 96-well plate (Corning Inc.,
Corning, NY). Caspase-3/7 activity in LX-2 cells was quantified utilizing the commercially
available Apo-ONE detection assay kit (Apo-ONE homogeneous caspase-3/7 assay,
Promega Corporation, Madison, WI) according to the manufacturer’s instructions.
Fluorescence intensity was measured using a fluorescence plate reader FLx 800 Microplate
(BIO-TEK Instruments, Winooski, Vermont). The amount of fluorescent product generated
is proportional to the amount of caspase-3/7 cleavage activity present in the sample and is
expressed as RFU (Relative Fluorescence Units).
Immunoblot analysis
Whole cell lysates were obtained as previously described by us in detail30. Protein
concentration of the supernatant was determined by the Bradford assay (Bio-Rad, Hercules,
CA). Proteins were electrophoretically resolved by 15% SDS-PAGE and immobilized on a
nitrocellulose membrane. Membranes were blocked in 5% non-fat dairy milk in Wash buffer
(TBS-T; 20 mM Tris, pH 7.4, 150 mM NaCl, 0.1% Tween-20) was employed. Blots were
incubated with primary antibodies at 4°C overnight and with secondary antibodies at room
temperature for 1 hour. The following primary antibodies were used: mouse anti-hNoxa
monoclonal antibody (114C307.1, dilution 1:1000, Alexis Biochemicals, Axxora Platforms,
San Diego, CA), rat anti-Bim monoclonal antibody (MAB17001, 1:1000, Chemicon,
Milipore Corporation, Billerica, MA), rabbit anti-Puma polyclonal antibody (3043, 1:1000,
Prosci Incorporated, Poway, CA), goat anti-Bid polyclonal antibody (AF860, 1:1000, R&D
System, Minneapolis, MN), rabbit anti-Bad polyclonal antibody (sc-7869, 1:1000, Santa
Cruz Biotechnology, Santa Cruz, CA), goat anti-actin polyclonal antibody (sc-1615, 1:2000,
Santa Cruz Biotechnology), rabbit anti-Bik polyclonal antibody (sc-10770, 1:1000, Santa
Cruz Biotechnology), rabbit anti-Bak polyclonal antibody (sc-832, 1:1000, Santa Cruz
Biotechnology), rabbit anti-S-probe polyclonal antibody (sc-802, 1:1000, Santa Cruz
Biotechnology), and finally, mouse monoclonal antibody to Į-tubulin (T6557, 1:5000,
Sigma Pharmaceuticals, St. Louis, MO). Peroxidase-conjugated secondary antibodies
(dilution 1:3000, Biosource International, Camarillo, CA) were used to detect antigen-
antibody complexes. These complexes were visualized using enhanced chemiluminescent
substrate (ECL, Amersham, Arlington Heights, IL) and were exposed to Kodak X-OMAT
films (Eastman Kodak, Rochester, NY). Either actin or Į-tubulin were used as loading
controls.
Reverse Transcription Polymerase Chain Reaction (RT-PCR)
Total RNA was isolated using TRIzol reagent (Invitrogen, Carlsbad, CA), and reverse-
transcribed using random primers and Moloney leukemia virus reverse transcriptase
(Invitrogen, Carlsbad, CA). PCR primers used for human Noxa were as follows: forward 5’-
GCA GAG CTG GAA GTC GAG TG-3’ and reverse 5’-AGC AGA AGA GTT TGG ATA
TCA G-3’ (yielding a 101 bp-product). Commercially available primers for ribosomal 18S
RNA (Ambion, Austin, TX) were used as internal controls. Quantification of the
complementary DNA template was performed with real-time polymerase chain reaction
using the Light Cycler (Roche Molecular Biochemicals, Mannheim, Germany) as we have
previously described in detail29.
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Noxa mRNA and protein half-life
To examine the effect of proteasome inhibition on the half-life of Noxa mRNA, LX-2 cells
were treated with media and vehicle containing 10 µmol/L MG-132 (Calbiochem, CA) in
the presence or absense of 5 µmol/L actinomycin D (Sigma-Genosys, Woodlands, TX).
Using this approach, at each selected time interval, total cellular RNA was isolated for RT-
PCR of Noxa. To examine the effect of the proteasome inhibition on the half-life of Noxa
protein, LX-2 cells were treated with vehicle in the presence and absence of MG-132 plus
cyclohexamide 20 µg/ml for 0–8 hours. At the selected time interval, cells were lysed, and
the lysates subjected to immunoblot analysis for Noxa as described above. Noxa and actin
bands were quantified as previously described by us in detail31. The half-life was
determined by t1/2 = ln(2)/Ȝ, where Ȝ is the decay constant.
Small interfering RNA (siRNA) experiments
RNA interference was used to silence Noxa gene expression in LX-2 cells. Noxa siRNA
sense 5'-GGA GAU UUG GAG ACA SAA CUtt-3' and anti-sense 3'-AGU UUG UCU CCA
AAU CUC Ctg-5' were purchased from Ambion (Austin, TX). Transient gene silencing was
attained by transfection of siRNA into cells using siPORT lipid transfection reagent
(Ambion) according to the manufacturer’s instructions. Scrambled siRNA was used as
control. Cells were transiently transfected in 6-well plates at 30% confluency. We used a
final concentration of 100 nM Noxa siRNA by using 6 µL of siPORT lipid in a total
transfection volume of 1 mL of OPTIMEM (Gibco-Invitrogen Corporation, Carlsbad, CA).
After 3 hours of transfection, 1.5 ml of medium per well was added.
Stable transfection of S-peptide-tagged human A1 expression plasmid
The human A1 cDNA was amplified from HEL cells by rt-PCR (forward primer 5’-
GTATCTGGTACCACAGACTGTGAATTTGGATAT-3 ’, reverse primer 5 ’-
GCTACTGAATTCTCAACAGTATTGCTTCAGG-3’) and subcloned into the KpnI and
EcoRI sites of pSPN to yield the S peptide epitope tag fused to the N terminus of A132. The
plasmid was subjected to nucleotide sequencing for confirmation. An S-peptide epitope tag
was then added as previously described by us31. The plasmid was subjected to nucleotide
sequencing for confirmation. Transfection with the S-peptide-tagged A1 expression plasmid
was performed using a standard lipofectamine method (Life Technologies, Inc.,
Gaithersburg, MD). Stably transfected LX-2 clones were selected in medium containing
1200 µg/ml G418. Individual colonies were sub-cloned and screened for A1 protein
expression by immunoblot analysis for the s-peptide tag. Established clones were grown in
DMEM supplemented with 10% fetal bovine serum, 10% bovine calf serum, 100,000 units/
L penicillin, 100 mg/L streptomycin, and 1200 mg/L G418.
Affinity purification of S-peptide-tagged A1
Cells were lysed in buffer containing 50 mm Tris (pH 7.4), 150 mM NaCl, 1 mM EDTA,
1mM PMSF, 1mM Na3VO4, 100mM NaF, 20 mM microcystin, 2% CHAPS and Complete
Protease Inhibitor as per manufactures protocol. Lysates (1 mL) were centrifuged at 13000 g
for 15 minutes to eliminate insoluble matter. Supernatant was transferred to fresh tubes and
100 µL of S-protein Agarose (Novagen) was added. Samples were gently agitated overnight
at 4°C. Samples were centrifuged at 10000 g for 1 min and supernatent discarded.
Remaining S-agarose was washed 6 times with 1 mL volumes of the previous lysis buffer
minus CHAPS. Following the final wash an equal volume (100 µL) of 2X Laemmli sample
buffer was added. Samples were boiled for 10 minutes and resolved by SDS-PAGE and
subjected to immunoblot analysis as described above.
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Immunocytochemistry
Cells were cultured on 6 well plates containing coverslips. After the treatment, the medium
was aspirated, and the cells were washed 3 times with phosphate-buffered saline (PBS) and
then fixed with 4% paraformaldehyde in PBS containing 0.1 m PIPES, 1 mm EGTA, and 3
mm MgSO4 for 15 min at 37 °C. After the second wash with PBS, cells were permeabilized
using 0.0125% (w/v) CHAPS in PBS at room temperature for 15 min. Cells were then
incubated in PBS containing 5% goat serum at room temperature for an hour. After
incubation with rabbit anti-Bak NT antisera (1:300 Upstate, Lake Placid, NY) overnight at 4
°C, cells were washed 3 times with PBS and incubated with Alexa Fluor 488-conjugated
goat anti-rabbit IgG (Molecular Probes) for 1 h at 37 °C. Cells were then washed 3 times in
PBS and 3 times in H2O, mounted onto slides using a ProLong Antifade kit with DAPI
(Molecular Probes), and imaged by confocal microscopy with excitation and emission
wavelengths of 488 and 505–580 nm (Alexa Fluor 488) and 364 and 385–470 nm (DAPI),
respectively.
Reagents
DAPI, OPH-19 Q-VD-OPH, MG-132 in solution (474791) and inhibitor Bay 11–70829
were purchased from Calbiochem (La Jolla, CA). Cyclohexamide and actinomycin D
(A9415) were from Sigma Pharmaceuticals (St. Louis, MO). S-protein agarose (69704) was
purchased from Novagen, (San Diego, CA).
Data analysis
All data are expressed as the mean ± standard error of the mean (SEM), representing at least
three separate experiments, unless otherwise specified. Analysis of variance (ANOVA) was
used for comparing differences between groups and to correct for multiple comparisons, a
Bonferroni post-hoc correction was employed. A p value less than 0.05 was considered
statistically significant. All statistical analyses were performed using In-Stat Software
(Graph Pad, San Diego, CA).
RESULTS
MG-132 treatment induce expression of Noxa protein
The proteasome inhibitor MG-132 induced apoptosis in the human HSC, LX-2 cell line, in a
time- and concentration-dependent manner (Fig. 1A and B). Maximal apoptosis was 50–
60% after 24 hour treatment with MG-132, 10 µmol/L. M G-132 cytotoxicity was caspase-
dependent as it was completely abrogated by the pan-caspase inhibitor QVD (Fig. 1A).
Having established the time course and the dose dependence for MG-132-mediated LX-2
cells apoptosis, we next examined the cellular expression of BH3-only proteins. Noxa, Bim,
Puma, Bad and Bid were expressed at the protein level in LX-2 cells (Fig. 2A). In contrast,
protein expression of Bmf, Hrk and Bik was not detected by immunoblot analysis. Protein
levels of Noxa and Bim increased after exposure of the cells to MG-132 (Fig. 2A). In
particular, Noxa protein levels increased by 22-fold, as measured by densitometric analysis
of immunoblots from triplicate experiments. This expression of Noxa by MG-132 treatment
was observed not only in LX-2 cells but also in isolated rat primary HSCs (Fig 2B). Since
we have previously demonstrated that inhibiting Bim expression by siRNA did not prevent
MG-132-mediated apoptosis10, we focused the remainder of this study on the role of Noxa
in apoptosis by MG-132.
Noxa is up-regulated by transcriptional and post-transcriptional mechanisms
In addition to the increase in Noxa cellular protein levels during proteasome inhibition, we
also observed a 16-fold increase in steady state Noxa mRNA (Fig. 3). To ascertain whether
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MG-132 increased Noxa mRNA steady state levels by stabilizing Noxa mRNA, its half-life
was quantified in the presence of the transcription inhibitor, actinomycin D. MG-132
treatment of LX-2 cells did not increase the half-life of Noxa mRNA (Fig. 4A). Thus, in the
absence of Actinomycin D, MG-132 increased Noxa mRNA levels by 16-fold, while in the
presence of the transcriptional inhibitor, cells treated with MG-132 did not have higher
Noxa mRNA levels than control (the slight decrease compared to control cells, 26% at 6
hours, was not statistically significant). Thus de novo transcription was required in order to
observe increased Noxa mRNA levels in MG-132 treated cells compared to control,
suggesting the increase in steady state mRNA reflected enhanced transcription. Consistent
with its ability to block degradation of proteins by the proteasome, MG-132 prolonged the
half-life of Noxa protein (Fig. 4B). The calculated half-life of Noxa protein was 22 minutes,
which was increased up to 20 hours in the presence of MG-132. Thus, proteasome inhibition
appears to increase cellular levels of Noxa by both transcriptional and post-transcriptional
mechanisms.
Noxa is essential for apoptosis by proteasome inhibition
To ascertain if Noxa is essential for mediating MG-132 apoptosis, its protein expression was
knocked down using siRNA technology. First, we verified the efficacy and specificity of the
siRNAs targeting Noxa. Indeed, its protein level was reduced 92% by this siRNA during
proteasome treatment (Fig. 5A). Knock down of Noxa was specific as cellular protein levels
of Bim were unaltered. Having demonstrated the efficacy of Noxa siRNA in reducing Noxa
cellular protein levels, cells transfected with Noxa siRNA were treated with MG-132 and
apoptosis was quantified. LX-2 cells transfected with Noxa siRNA demonstrated a reduction
of 54% in MG-132 cytotoxicity by both morphologic criteria and caspase-3/7 activity (Fig.
5A and 5B). In contrast, scrambled siRNA-transfected cells were not protected against
MG-132 cytotoxicity. Taken together, these data suggest that MG-132-induced apoptosis is,
in part, Noxa-dependent.
A1 partially protects LX-2 cells from apoptosis by MG-132
We have previously reported that proteasome inhibition decreased A1 mRNA expression in
LX-2 cells, and further that A1 gene silencing by siRNA induced LX-2 cell death10. Thus,
A1 acts as a mediator of LX-2 survival. To determine whether enforced expression of A1
was sufficient to protect cells treated with MG-132, we measured apoptosis in LX-2 cells
stably transfected with an A1 expression plasmid (termed LX-2/A1). Compared to parental
cells, LX-2/A1 cells had partial protection from MG-132-induced apoptosis (Fig. 6A).
However, protection was only partial, suggesting that A1 is functionally inhibited in cells
treated with MG-132.
Noxa associates with A1 upon MG-132 treatment
It has been proposed that anti-apoptotic Bcl-2 proteins such as A1 are functionally
neutralized following binding by BH3-only proteins27. Based on this model, we considered
that the anti-apoptotic activity of A1 may be inhibited by binding to Noxa. We employed
LX-2/A1 cells stably expressing S peptide-tagged A1 to ensure adequate A1 expression as
well as providing an epitope tag to facilitate pulldown, given previous difficulty in using
commercial antibodies for A1 immunoprecipitation. The ability of A1 to bind Noxa was
then examined as described under the experimental procedure section. Affinity purification
of S peptide-tagged A1 from whole cell lysates revealed binding of Noxa to this anti-
apoptotic protein following treatment of LX-2 cells with MG-132 (Fig. 6B). These data are
compatible with neutralization of A1 by Noxa.
A1, in part, antagonizes cell death signals by binding to the pro-apoptotic, multidomain,
Bcl-2 protein Bak14. Therefore, we postulated that if Noxa binds A1 disabling its function,
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Bak would not bind as efficiently to A1. To test the A1:Bak interaction we utilized affinity
purification of S peptide-tagged A1, as above, and probed the pulldown with antiserum
specific for Bak. In vehicle-treated cells, A1 and Bak could be co-precipitated (Fig. 6C). We
observed a increase in S-peptide tagged A1 protein levels upon MG-132 treatment in this
experiment, possibly due to decreased degradation of A1 by the proteasome. When LX-2/A1
cells were treated with MG-132, both polypeptides were recoved in higher amounts,
however the Bak/A1 ratio was decreased compared to vehicle. One interpretation of these
data is that Noxa binding to A1 decreased the Bak/A1 ratio, permiting Bak derepression and
activation.
We next investigated Bak activation in LX-2 cells treated with MG-132. Activation of Bak
can be visualized by immunofluorescent staining utilizing antiserum specific for the N
terminal of Bak. This epitope is normally not accessible to the antibody for binding,
however, upon activation, Bak undergoes a conformational change facilitating staining by
the N terminal-specific Bak antibody33. Indeed, we observed Bak activation in MG-132
treated LX-2 cells (Fig. 6D). Taken together, these data further implicate Noxa inhibition of
A1 as a mechanism contributing to stellate cell death by proteasome inhibitors.
DISCUSSION
The results of this study provide new insight into the mechanisms of stellate cell apoptosis.
The results indicate that during pharmacologic proteasome inhibition: i) Noxa protein levels
are increased by both transcriptional and post-translational mechanisms; ii) siRNA targeted
knock down of Noxa attenuates apoptosis and iii) Noxa likely exerts its pro-apoptotic
activity, in part, by binding to the anti-apoptotic protein A1 thus derepressing Bak. Each of
these results is discussed in greater detail below.
Proteasome inhibition has been previously demonstrated to reduce liver injury, attenuate
hepatic fibrosis, and induce stellate cell apoptosis in vivo and in vitro, respectively10, 11.
Therefore, we employed cultured HSC to continue our exploration of the mechanisms
modulating HSC apoptosis. The current study focused on the BH3-only proteins involved in
triggering apoptosis, as these proteins act as biosensors of cell stress and initiate the critical
cellular cascades culminating in cellular demise. Of the five BH3-only proteins expressed by
LX-2 cells, only two increased during proteasome inhibitor triggered apoptosis, Bim and
Noxa. We have previously demonstrated that siRNA knockdown of Bim was insufficient to
attenuate apoptosis in this model10; therefore, Noxa appears to be the primary BH3-only
protein contributing to HSC apoptosis in this model. The increase in Noxa following
proteasome inhibition was associated with an increase both in its mRNA and protein half-
life. These observations suggest proteasome inhibition increases cellular Noxa levels by
both transcriptional and post-translational mechanisms. Although p53 is a potent inducer of
Noxa, its increase during proteasome inhibition is p53-independent34. Wang and co-workers
have recently demonstrated that proteasome inhibition induces endoplasmic reticulum stress
(unfolded protein response) which increases Noxa transcription via the transcription factors
ATF3 and ATF435. Fernandez et al. have also suggested that proteasome inhibition extends
the half-life of Noxa22, an assumption which we were able to directly confirm. Collectively,
these composite observations suggest the increase of cellular Noxa levels during proteasome
inhibition is multifactorial. The concept that endoplasmic reticulum stress is a potent inducer
of Noxa suggests that this mechanism of inducing Noxa and hence stellate cell apoptosis
warrants further therapeutic exploration.
siRNA targeted knockdown of Noxa reduced LX-2 apoptosis by the proteasome inhibitor
MG-132. Prior studies have also implicated Noxa as a key mediator of apoptosis in cancer
cells during proteasome inhibition22, 23, 26, 34–36. Thus, activated stellate cells appear to
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respond to proteasome inhibition much like transformed cells. This observation gives
credence to the concept that when activated, stellate cells assume many features of
transformed cells with enhanced proliferation, ability to migrate, and differential sensitivity
to pro-apoptotic stimuli3.
We have previously demonstrated that survival of activated LX-2 cells is dependent upon
expression of the pro-apoptotic protein A1. BH3-only proteins differentially bind to pro-
apoptotic proteins14, and Noxa peptides demonstrate high affinity binding to Mcl-1 and A1
in vitro27. We have extended these observations by demonstrating for the first time to our
knowledge binding of Noxa protein to A1 in a cellular context. Upon binding BH3-only
proteins, anti-apoptotic proteins such as A1 lose their ability to repress activation of pro-
apoptotic multidomain proteins, such as Bak14. Given this information, Noxa likely triggers
apoptosis, in part, by binding to and inhibiting the pro-survival effect of A1 on Bak. Indeed,
the Bak/A1 ratio was decreased in cells upon MG-132 treatment while Bak activation was
increased. It remains possible that Noxa promotes Bak activation by additional, as yet
unknown, mechanisms.
Inducing stellate cell apoptosis remains a viable therapeutic strategy for treating hepatic
fibrosis37. Our current studies suggest that approaches to enhance Noxa expression facilitate
apoptosis induction in this liver cell type. Noxa likely promotes stellate cell apoptosis by
binding A1, a dominant pro-survival protein for these cells. Other cellular events likely also
contribute to cellular demise in this model of cell death by proteasome inhibition. Therefore,
it will be necessary to confirm these observations in other models, but if our results are
confirmed in additional models, stellate cell specific Noxa expression may provide a
foundation for the development of new therapeutic approaches for hepatic fibrosis.
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Figure 1. MG-132 induces apoptosis in LX-2 cells, which is inhibited by pan-caspase inhibitor
(A) LX-2 cells were incubated for 24 hours in the presence of increasing concentrations of
MG-132 (0, 2.5, 5, 10 µmol/L) and in the presence of the pan-caspase inhibitor QVD at 5
µmol/L for 24 hours. MG-132 and QVD were prepared in DMSO as a vehicle. All data were
expressed as mean ± standard error from three individual experiments. * p < 0.01 (10 µmol/
L MG-132 treated cells vs. 10 µmol/L MG-132 plus QVD treated cells) (B) LX2 cells were
treated by MG-132 (10 µmol/L) for indicated time. * p < 0.01 (MG-132 treated cells vs.
vehicle treated cells)
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Figure 2. MG-132 induces expression of Noxa protein in LX-2 cells and rat primary HSC cells
(A) LX-2 cells were treated with MG-132 at 10 µmol/L for 24 hours, and a vehicle (DMSO)
was used as control in the absence of MG-132. Cells were lysed and subjected to
immunoblot analysis for indicated proteins. Actin was used as control for protein loading.
(B) Rat primary HSC were treated with MG-132 10 µmol/L for 24 hours and subjected to
immunoblot analysis using anit-Noxa.
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Figure 3. Noxa mRNA expression increases after treatment with MG-132
LX-2 cells were treated in the presence and absence of MG-132 at 10 µmol/L for indicated
time. Total cellular RNA was extracted and analyzed by quantitative real-time PCR. Fold
induction was determined after normalization to 18S housekeeping gene. All data represent
the mean ± standard error of three separate experiments. * p < 0.05 (MG-132 treated cells
vs. vehicle treated cells)
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Figure 4. MG-132 effect on Noxa mRNA and protein half-life
(A) LX-2 cells were treated with Actinomycin D at 5 µmol/L and MG-132 at 10 µmol/L or
vehicle for the indicated times and Noxa mRNA was quantified by RT-PCR. Noxa mRNA
levels are expressed as a percent of signal compared to time zero. Data are mean +/ᙐ
standard error from three samples, and are representative of three independent exeriments.
(B) Cells were treated in the presence of the protein synthesis inhibitor cyclohexamide 20
µmol/L plus QVD at 5 µmol/L and the presence and absence of MG-132 at 10 µmol/L for
the indicated time. Cells were lysed and subjected to immunoblot analysis for anti-Noxa.
Actin was used as control for protein loading.
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Figure 5. Noxa is essential for apoptosis by proteasome inhibition
(A) LX-2 cells were transiently transfected with a specific small-interfering RNA (siRNA)
construct targeting Noxa or a control siRNA (scramble) for 24 hours; next cells were treated
in the presence of MG-132 at 10 µmol/L for 24 hours. (A) Apoptosis was quantified using
DAPI staining and fluorescence microscopy. Data were expressed as mean ± standard error
from three individual experiments. * p < 0.05 (Noxa siRNA plus MG-132 treated cells vs.
scramble siRNA plus MG-132 treated cells) (B) In parallel studies, apoptosis was also
assessed by measuring caspase-3/7 activity. * p < 0.05 (Noxa siRNA plus MG-132 treated
cells vs. scramble siRNA plus MG-132 treated cells)
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Figure 6. A1 is functionally inhibited by MG-132 treatment and Noxa association
(A) LX-2 cells stably transfected with S peptide-tagged A1 (LX-2/A1) or parental LX-2
cells were treated with vehicle (DMSO) or MG-132 (10 µmol/L) for 24 hours followed by
DAPI nuclear staining. The percent of cells with apoptotic nuclear morphology was
quantified and expressed as mean +/ᙐ SEM. ** = p<0.01 by ANOVA with post-hoc
correction. (B) Noxa associates with S peptide-tagged A1 upon MG-132 treatment. LX-2/A1
cells were treated with the presence and absence of MG-132 at 10 µmol/L for 12 hours.
Whole cell lysates were prepared, S peptide-tagged A1 was pulled down using S protein-
agarose beads. S tagged-peptide A1 was removed from the beads by boiling in Laemnli
sample buffer and resolved by SDS-PAGE. Immunoblot analysis was employed to identify
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S peptide-tagged A1 and Noxa. (C) Affinity purified complexes prepared as in panel B from
LX-2/A1 cells were probed with antisera to Bak and A1. (D) Proteasome inhibitor induces
Bak activation. Cells were treated with either vehicle or MG-132 at 10 µmol/L for 12 hours
and were subjected to Bak immunofluorescence study using antiserum specific for the N
terminus of Bak. Upon Bak activation, this epitope is no longer masked within the protein
and becomes available for antibody binding upon Bak conformational change.
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